BIOCON LTD is a generic drug manufacturer focused on Neurology, Oncology. Key products include PEMETREXED.
BIOCON LTD at a Glance
- Fast trial execution (17 months median completion)
BIOCON LTD's Key Drugs
BIOCON LTD's core commercial portfolio centers on PEMETREXED, spanning Neurology and Oncology — its most strategically important drugs approved in the last 15 years.
BIOCON LTD's Recent FDA Approvals
New NDA/BLA approvals for BIOCON LTD over the last two years — novel drugs only, excluding generics and label supplements.
BIOCON LTD's Therapeutic Areas
BIOCON LTD's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BIOCON LTD's Top Competitors
BIOCON LTD's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BIOCON LTD Pipeline Snapshot
Active clinical trials for BIOCON LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PEMETREXED leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/3 completed
- • Speed: 17 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-12-04
- Latest
- 2026-03-12
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges